Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- CVS Ramps Up Retail Clinics with Provider Affiliations
- 4 Tectonic Shifts Shaking Up Healthcare
- As States Regulate Provider Competition, Common Threads Emerge
- Medical Errors Third Leading Cause of Death, Senators Told
- Contradictory Obamacare Rulings Issued by Appellate Courts
- As HIPAA Breaches Accelerate, Tools Lag
- Study Puts Spotlight on Preventing Fall-Related Injuries
- Wanted: Nurse PhDs
- Roundtable: Life After a Healthcare Organization Acquisition
- Recruiting Retired Clinicians